Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 111

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 111
---
 We expect to continue to incur significant expenses and operating losses for the foreseeable future as we continue to expand research and development efforts, enhance our existing consumer products, services and business model, broaden our customer base, work with regulatory agencies, and hire additional employees to support our growth. Any future losses may have an adverse effect on our shareholders’ equity and working capital, which could negatively impact our operations and your investment in us. A failure to sustain or grow our revenue levels and to maintain profitability may negatively affect our business, financial condition, results of operations and cash flows, and could cause the market price of our common share to decline. Our prospects must be considered in light of the risks and difficulties frequently encountered by companies in a similar stage of development, particularly companies in new and rapidly evolving markets such as ours. These risks include an evolving and unpredictable business model and the management of growth. To address these risks we must (i) increase our customer base; (ii) continue to implement and successfully execute our business and marketing strategy; (iii) successfully enter into other strategic collaborations or relationships; (iv) obtain access to capital on acceptable terms and effectively utilize that capital; identify, attract, hire, retain, motivate and successfully integrate employees; (v) continue to expand, automate and upgrade our laboratory, technology and data systems; (vi) obtain, maintain and expand coverage and reimbursement by healthcare payers; (vii) obtain and maintain sufficient payment by partners, institutions and individuals; (viii) provide rapid test turnaround times with accurate results at low prices; (ix) provide superior customer service; and (x) respond to competitive developments, among other things. We cannot assure you that we will be successful in addressing these risks, and the failure to do so could have an adverse impact on our business, financial condition, results of operations and growth prospects. We face intense competition and may not be able to compete successfully with existing or new competitors in our industry. With the development of next generation sequencing, the clinical genetics market is becoming increasingly competitive and we expect this competition to intensify significantly in the next five to ten years. We face competition from a variety of sources, including: •companies such as Synlab; Centogene N.V.; Invitae Corporation; Mendelics Análise Genômica S.A., Diagnósticos da América S.A.; Igenomix S.L.; Nimgenetics Genómica Y Medicina, S.L.; Color Health, Inc.; Bitgenia Brasil Ltda.; Biomakers S